Neurogene Inc

Neurogene Inc.’s stock surged 37% after the FDA approved its Rett syndrome gene therapy trial design, with analyst support from Stifel further boosting investor confidence.

Neurogene Inc.’s stock price has experienced significant volatility, with a 52-week high of $74.49 and a 52-week low of $6.875, raising questions about the company’s stability and future prospects in the biotech industry.

Neurogene Inc, a biopharmaceutical company focused on genetic medicines for neurological diseases, is navigating turbulent market fluctuations despite its commitment to innovation and patient care.